389 related articles for article (PubMed ID: 26945421)
1. Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
Choi JS; Ko ES; Ko EY; Han BK; Nam SJ
Medicine (Baltimore); 2016 Mar; 95(9):e3000. PubMed ID: 26945421
[TBL] [Abstract][Full Text] [Related]
2. Role of dynamic contrast-enhanced MRI in evaluating the association between contralateral parenchymal enhancement and survival outcome in ER-positive, HER2-negative, node-negative invasive breast cancer.
Shin GW; Zhang Y; Kim MJ; Su MY; Kim EK; Moon HJ; Yoon JH; Park VY
J Magn Reson Imaging; 2018 Dec; 48(6):1678-1689. PubMed ID: 29734483
[TBL] [Abstract][Full Text] [Related]
3. Association between contralateral background parenchymal enhancement on MRI and outcome in patients with unilateral invasive breast cancer receiving neoadjuvant chemotherapy.
Rella R; Bufi E; Belli P; Scrofani AR; Petta F; Borghetti A; Marazzi F; Valentini V; Manfredi R
Diagn Interv Imaging; 2022 Oct; 103(10):486-494. PubMed ID: 35585020
[TBL] [Abstract][Full Text] [Related]
4. Decreased background parenchymal enhancement of the contralateral breast after two cycles of neoadjuvant chemotherapy is associated with tumor response in HER2-positive breast cancer.
You C; Gu Y; Peng W; Li J; Shen X; Liu G; Peng W
Acta Radiol; 2018 Jul; 59(7):806-812. PubMed ID: 29065702
[TBL] [Abstract][Full Text] [Related]
5. Background parenchymal enhancement on breast MRI: association with recurrence-free survival in patients with newly diagnosed invasive breast cancer.
Lim Y; Ko ES; Han BK; Ko EY; Choi JS; Lee JE; Lee SK
Breast Cancer Res Treat; 2017 Jun; 163(3):573-586. PubMed ID: 28349273
[TBL] [Abstract][Full Text] [Related]
6. Changes in background parenchymal enhancement in HER2-positive breast cancer before and after neoadjuvant chemotherapy: Association with pathologic complete response.
Dong JM; Wang HX; Zhong XF; Xu K; Bian J; Feng Y; Chen L; Zhang L; Wang X; Ma DJ; Wang B
Medicine (Baltimore); 2018 Oct; 97(43):e12965. PubMed ID: 30412117
[TBL] [Abstract][Full Text] [Related]
7. Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients.
Garimella V; Qutob O; Fox JN; Long ED; Chaturvedi A; Turnbull LW; Drew PJ
Eur J Surg Oncol; 2007 Mar; 33(2):157-61. PubMed ID: 17085007
[TBL] [Abstract][Full Text] [Related]
8. Survival outcomes of breast cancer patients who receive neoadjuvant chemotherapy: association with dynamic contrast-enhanced MR imaging with computer-aided evaluation.
Yi A; Cho N; Im SA; Chang JM; Kim SJ; Moon HG; Han W; Park IA; Noh DY; Moon WK
Radiology; 2013 Sep; 268(3):662-72. PubMed ID: 23592770
[TBL] [Abstract][Full Text] [Related]
9. Relationship between background parenchymal enhancement on breast MRI and pathological tumor response in breast cancer patients receiving neoadjuvant chemotherapy.
Oh SJ; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH
Br J Radiol; 2018 Jul; 91(1088):20170550. PubMed ID: 29848015
[TBL] [Abstract][Full Text] [Related]
10. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy.
Choi BB; Kim SH
Acta Radiol; 2015 Jul; 56(7):790-7. PubMed ID: 24951616
[TBL] [Abstract][Full Text] [Related]
11. Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI.
Chen JH; Yu H; Lin M; Mehta RS; Su MY
Magn Reson Imaging; 2013 Nov; 31(9):1465-71. PubMed ID: 23992630
[TBL] [Abstract][Full Text] [Related]
12. Quantitative background parenchymal enhancement to predict recurrence after neoadjuvant chemotherapy for breast cancer.
Moliere S; Oddou I; Noblet V; Veillon F; Mathelin C
Sci Rep; 2019 Dec; 9(1):19185. PubMed ID: 31844135
[TBL] [Abstract][Full Text] [Related]
13. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.
Loo CE; Rigter LS; Pengel KE; Wesseling J; Rodenhuis S; Peeters MJ; Sikorska K; Gilhuijs KG
Breast Cancer Res; 2016 Aug; 18(1):82. PubMed ID: 27495815
[TBL] [Abstract][Full Text] [Related]
14. Background parenchymal signal enhancement ratio at preoperative MR imaging: association with subsequent local recurrence in patients with ductal carcinoma in situ after breast conservation surgery.
Kim SA; Cho N; Ryu EB; Seo M; Bae MS; Chang JM; Moon WK
Radiology; 2014 Mar; 270(3):699-707. PubMed ID: 24126372
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of DCE-MRI in breast cancer patients undergoing neoadjuvant chemotherapy: a comparison with traditional survival indicators.
Pickles MD; Lowry M; Manton DJ; Turnbull LW
Eur Radiol; 2015 Apr; 25(4):1097-106. PubMed ID: 25424563
[TBL] [Abstract][Full Text] [Related]
16. Association between background parenchymal enhancement and tumor response in patients with breast cancer receiving neoadjuvant chemotherapy.
Rella R; Bufi E; Belli P; Petta F; Serra T; Masiello V; Scrofani AR; Barone R; Orlandi A; Valentini V; Manfredi R
Diagn Interv Imaging; 2020 Oct; 101(10):649-655. PubMed ID: 32654985
[TBL] [Abstract][Full Text] [Related]
17. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
[TBL] [Abstract][Full Text] [Related]
18. Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.
Tahmassebi A; Wengert GJ; Helbich TH; Bago-Horvath Z; Alaei S; Bartsch R; Dubsky P; Baltzer P; Clauser P; Kapetas P; Morris EA; Meyer-Baese A; Pinker K
Invest Radiol; 2019 Feb; 54(2):110-117. PubMed ID: 30358693
[TBL] [Abstract][Full Text] [Related]
19. Time to surgery following neoadjuvant chemotherapy for breast cancer impacts residual cancer burden, recurrence, and survival.
Sutton TL; Schlitt A; Gardiner SK; Johnson N; Garreau JR
J Surg Oncol; 2020 Dec; 122(8):1761-1769. PubMed ID: 33125715
[TBL] [Abstract][Full Text] [Related]
20. Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response.
Preibsch H; Wanner L; Bahrs SD; Wietek BM; Siegmann-Luz KC; Oberlecher E; Hahn M; Staebler A; Nikolaou K; Wiesinger B
Eur Radiol; 2016 Jun; 26(6):1590-6. PubMed ID: 26382845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
